Prevention of heterotopic ossification in cases of hypertrophic osteoarthritis submitted to total hip arthroplasty. Etidronate or Indomethacin?
We present a study comparing etidronate or indomethacin for the prevention of heterotopic ossification after total hip arthroplasty in patients with hypertrophic osteoarthritis. 52 patients were divided in two groups. Group A (26 patients) received etidronate (20 mg/kg/day for 12 weeks) and Group B (26 patients) indomethacin 75 mg/day for 2 weeks. Mean follow up was 36 months (range, 18 to 50 months). The incidence of side effects was 15.4% in group A and 30.8% in group B (p=0.324). At 6 months there was no statistically significant difference in terms of clinical (p=0.532) and radiographic evaluation between the two groups (p=0.303). However, the cost of etidronate which may be as much as six times more expensive than that of indomethacin could not justify its routine prophylactic use.
Vasileiadis
G I
GI
1st Orthopaedic Department, University of Athens, ATTIKON University General Hospital, Athens, Greece.
Sakellariou
V I
VI
Kelekis
A
A
Galanos
A
A
Soucacos
P N
PN
Papagelopoulos
P J
PJ
Babis
G C
GC
D000368:Aged; D019644:Arthroplasty, Replacement, Hip; D012968:Etidronic Acid / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009999:Ossification, Heterotopic / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control*; D015207:Osteoarthritis, Hip / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D016896:Treatment Outcome
D012968:Etidronic Acid; D007213:Indomethacin